. 2009 Sep-Oct;3(5 Suppl 2):S62–S66.

Table 2:

Phase II trials of novel “targeted” agents in neuroendocrine tumors

Agent	Molecular Target(s)	No. Patients	Tumor	Tumor Response Rate (%)	Reference
Imatinib	PDGFR-α, -β; KIT; Bcr-Abl	27	Carcinoid	4	Yao et al, 2007³⁴
Bevacizumab + octreotide	VEGF	22	Carcinoid	18	Yao et al, 2008²¹
Sunitinib	VEGFR, PDGFR, C-Kit, RET, FLT3	41	Carcinoid	2	Kulke et al, 2008²³
Sunitinib	VEGFR, PDGFR, C-Kit, RET, FLT3	66	Pancreatic endocrine	16	Kulke et al, 2008²³
Sorafenib	VEGFR, B-Raf	50	Carcinoid	7	Hobday et al, 2007²²
Sorafenib	VEGFR, B-Raf	43	Pancreatic endocrine	11	Hobday et al, 2007²²
Gefitinib	EGFR	40	Carcinoid	3	Hobday et al, 2006³⁵
Gefitinib	EGFR	31	Pancreatic endocrine	6	Hobday et al, 2006³⁵
Temsirolimus	mTOR	21	Carcinoid	5	Duran et al, 2006²⁵
Temsirolimus	mTOR	15	Pancreatic endocrine	7	Duran et al, 2006²⁵
Everolimus (RAD001) + octreotide	mTOR	30	Carcinoid	17	Yao et al, 2008²⁶
Everolimus (RAD001) + octreotide	mTOR	30	Pancreatic endocrine	27	Yao et al, 2008²⁶

Abbreviations: EGFR = epidermal growth factor receptor; mTOR = mammalian target of rapamycin; PDGFR = platelet-derived growth factor receptor; VEGF = vascular endothelial growth factor; VEGFR = vascular endothelial growth factor receptor